Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of albumin-bound paclitaxel for malignant tumors
ChiCTR2400083939Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel in Non-hematologic malignancy, breast cancer, ovarian cancer and 5 more, sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Safety. Planned start May 2024; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
Non-hematologic malignancybreast cancerovarian cancerbronchial carcinomaCervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400083939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083939.